ABSTRACT
fetal hypoglycemia, intrauterine growth restriction, and acute hypoxemia produce an 28 early activation of fetal HGP. To test the hypothesis that prolonged hypoxemia 29 increases factors which regulate HGP, studies were performed in fetuses that were bled 30 to anemic conditions (anemic, n=11) for 8.9 ± 0.4 days and compared to control fetuses 31 (n=7). Fetal arterial hematocrit and oxygen content were 32% and 50% lower, 32 respectively, in anemic vs. controls (p<0.005). Arterial plasma glucose was 15% higher 33 in the anemic group (p<0.05). Hepatic mRNA expression of phosphonenolpyruvate 34 carboxykinase (PCK1) was 2-fold higher in the anemic group (p<0.05). Arterial plasma 35 glucagon concentrations were 70% higher in anemic fetuses compared to controls 36 (p<0.05) and they were positively associated with hepatic PCK1 mRNA expression 37 (p<0.05). Arterial plasma cortisol concentrations increased 90% in the anemic fetuses 38 (p<0.05), but fetal cortisol concentrations were not correlated with hepatic PCK1 mRNA 39 expression. Hepatic glycogen content was 30% lower in anemic vs. control fetuses 40 (p<0.05) and was inversely correlated with fetal arterial plasma glucagon 41 concentrations. In isolated primary fetal sheep hepatocytes, incubation in low oxygen 42 (3%) increased PCK1 mRNA 3-fold compared to incubation in normal oxygen (21%). 43
Together, these results demonstrate that glucagon and PCK1 may potentiate fetal HGP 44 during chronic fetal anemic hypoxemia. 45 46 KEY WORDS: Glucose, Oxygen, PEPCK, Glycogen, Hepatocyte 47
INTRODUCTION 49
Glucose is the principal energy substrate for the fetus and is essential for normal 50 fetal metabolism and growth. The transport of glucose from the mother to the fetus 51 occurs by facilitated diffusion across the placenta. Therefore, the rate of fetal glucose 52 uptake depends largely on the maternal arterial plasma glucose concentration (19) . 53
Normally, transported maternal arterial glucose is the sole source of fetal glucose and 54 there is no fetal hepatic glucose production (HGP) (20) . 55
As part of the transition to extrauterine life, fetal HGP is activated just prior to 56 delivery (13). At birth, infants have a period of reduced glucose intake when they are 57 removed from their placental glucose supply and their mother's milk is being 58 established. Thus, to avoid hypoglycemia the neonate must rely on endogenous HGP. 59
Fetal sheep at 0.97 gestation have increased endogenous HGP as well as higher 60 hepatic levels of the gluconeogenic enzymes phosphoenolpyruvate carboxykinase 61 (PEPCK, encoded by PCK1) and glucose-6-phosphatase (G6Pase, encoded by G6PC) 62 compared to 0.95 gestation (11, 13) . PEPCK catalyzes the rate-limiting step and 63
G6Pase catalyzes the final step in gluconeogenesis. Increased perinatal transcription of 64 PCK1 is activated by rising plasma concentrations of glucagon and glucocorticoids (13, 65 17, 36) . There also is activation of glycogenolysis by increased secretion and plasma 66 concentrations of glucagon and catecholamines around the time of birth (17, 36) . 67
Increased gluconeogenesis and glycogenolysis maintain glucose homeostasis in the 68
neonate by matching glucose utilization with increased HGP (36) . 69
Normal fetuses have little if any HGP prior to 0.97 gestation (11, 13) . Animal 70 studies, however, have shown that certain conditions can increase factors whichanemic fetus did not survive to necropsy following the metabolic study, but there were 137 no other unplanned fetal deaths. Fetal umbilical blood flow was calculated using an 138 ethanol tracer and the transplacental diffusion technique (32). Glucose, lactate, oxygen, 139 and ethanol were measured from four blood draws obtained from the fetal umbilical vein 140 and descending aorta after the ethanol tracer reached a steady state. During the study 141 period, fetal blood removed was replaced with a fetal transfusion of heparinized 142 maternal whole blood diluted with 0.9% NaCl to match the hematocrit of the fetal blood 143 (47). Nutrient uptake by the fetus was calculated using the Fick principle (32 
Fetal and Fetal Liver Weight 149
The day after the metabolic studies, the mother and fetus were euthanized (37). 150
Fetal organs were collected and weighed. A portion of the right lobe of the fetal liver 151 was snap frozen in liquid nitrogen and then stored at -80°C. One anemic fetus did not 152 survive to necropsy following the metabolic study. Other than not surviving to necropsy, 153 we did not detect anything unusual about this fetus and have included it in the in vivo 154
analysis. 155

Glycogen Content 156
Glycogen content in the liver was determined as previously described (29).
Results are expressed as milligrams glycogen per grams tissue (wet weight). 158
Real-time Quantitative PCR 159
RNA was extracted from pulverized liver tissue and reverse transcribed to cDNA. 160
Quantitative PCR was performed as previously described (50 phosphofructokinase 1 (PFK1), and endothelin 1 (EDN1) (6, 16, 39, 48, 50) . Additional 166 primers were developed and validated for vascular endothelial growth factor A (VEGFA; 167 forward: TTGCCTTGCTGCTCTACCTT; rev: GGGCACACACTCCAGACTTT), 168 erythropoietin (EPO; forward: CCCAGACACCAAGGTTAACT; rev: 169 GAAAGATAGCTTCTGAGAGCA), 6-phosphofructo-2-kinase/fructose-2,6-170 biphosphatase 1(PFKB1), and the glucagon receptor (GCGR; forward: 171 ATGCTGTTCGTCATCCCCTG; rev: AAGCGCAGAATCCACCAGAA). The 172 housekeeping genes GAPDH and RPS15 were not different between groups and were 173 used to normalize results for the genes of interest (14) . 174
Western Blotting 175
Tissue lysates were prepared from pulverized frozen liver tissue, and Western 176 immunoblotting was performed as previously described (50). PEPCK, G6Pase, 177 hepatocyte nuclear factor-4α (HNF4α), actin, protein kinase B (AKT), phosphorylated 178 AKT (S473/T308), adenosine monophosphate-activated protein kinase (AMPK),phosphorylated AMPK (T172), cyclic AMP response element binding-protein (CREB), 180 phosphorylated CREB (S133) were used as previously described (47,50). The 181 membrane for glucose regulated protein 78 kDa (GRP78) was blocked for 1 hour in 182
Tris-buffered saline with 0.01% Tween 20 (TBST; Bio-Rad) and 5% wt/vol nonfat dried 183 milk. A monoclonal rat IgG anti GRP78 antibody (Santa Cruz Biotech; Santa Cruz, CA) 184 was diluted to 1:500 in TBST with 5% bovine serum albumin and placed on the 185 membrane overnight. Quantification of bands was performed by densitometry (Image J) 186 or Image Studio (LI-COR) and normalized to actin. For phosphorylated proteins a ratio 187 to the densitometry of the respective total protein was calculated. 188
Primary Fetal Hepatocytes 189
Primary fetal hepatocytes were isolated from four additional late gestation fetal 190 
Statistical Analysis 203
Statistical analysis was performed using SAS version 9.1 or GraphPad Prism 6.0. 
RESULTS
213
Maternal and Fetal Biochemistry and Necropsy Data 214
Daily bleeding resulted in significant reduction in both the fetal arterial hematocrit 215 and oxygen content beginning on day 1 in the anemic group (p<0.001; Figure 1A , B). At 216 the end of the study period, when umbilical blood flow and fetal nutrient uptakes were 217 measured, the blood hematocrit and oxygen content were 32% and 50% lower, 218 respectively, in the anemic vs. control group. There were no differences in pH, partial 219 pressure of CO 2 , or arterial plasma lactate on any study day between groups (Table 1) . 220
There was a decrease in the partial pressure of oxygen and hemoglobin-oxygen 221 saturation in both groups over time, but the groups were not different from each other 222 ( Figure 1C, D) . By the end of the study, plasma glucose concentrations were 15% 223 higher in the anemic vs. control group (p<0.05; Figure 2A) . 224
There were no differences in maternal pH, partial pressure of oxygen, partial 225 pressure of CO 2 , oxygen-hemoglobin saturation (sO 2 ), oxygen content, hematocrit, 226 glucose, or lactate concentration on any day of study (Table 1) . 227
Fetal necropsy data are shown in Table 2 . The anemic fetuses had heavier right 228 ventricular weight compared to controls (p<0.05). There were no other differences 229 between the groups. 230
Fetal Hormones 231
Fetal arterial plasma norepinephrine and insulin concentrations were not 232 statistically different between the two groups ( Figure 3A, B) . Fetal arterial cortisolconcentrations were increased 90% on the final day in the anemic group compared to 234 baseline (p<0.05; Figure 3C ), but they were not different from the controls on the final 235 day ( Figure 3C ). By the final day of the study, arterial glucagon concentrations in 236 anemic fetuses were significantly increased compared to baseline and 70% higher than 237 controls (p<0.05; Figure 3D ). 238
Fetal Metabolic Studies 239
Umbilical blood flow, fetal glucose and lactate uptake rates, and the maternal to 240 fetal arterial glucose concentration difference were not different between groups (Table  241 1, Figure 2B ). The anemic fetuses had significantly lower whole-body oxygen utilization 242 despite having a higher oxygen extraction compared to controls (p<0.05; Figure 4A , B). 243
There was a significant correlation between fetal arterial oxygen content and fetal 244 oxygen extraction, such that at low oxygen contents there was increased fetal oxygen 245 extraction (p<0.001; Figure 4C ). 246
Hepatic PCK1, G6PC, and Glycogen 247
Hepatic PCK1 mRNA was 2-fold greater in the anemic group compared to 248 controls (p<0.05; Figure 5A ). The tendency for higher levels of hepatic G6PC mRNA in 249 anemic fetuses was not statistically significant ( Figure 5D ). Fetal arterial glucagon 250 concentrations were significantly correlated with both hepatic PCK1 and G6PC mRNA 251 levels (p<0.05; Figure 5B , E). Fetal arterial cortisol concentrations did not correlate with 252 either hepatic PCK1 or G6PC mRNA ( Figure 5C , F). The hepatic protein expressions of 253 PEPCK and glucose-6-phosphatase were not different between the groups (Table 3) . 254
Hepatic glycogen concentration was significantly lower in the anemic fetuses comparedto controls (p<0.05; Figure 5G ) and was inversely correlated to fetal arterial plasma 256 glucagon concentrations (p<0.05), but not fetal cortisol concentrations (Figure 5H, I) . 257
Cellular Nutrient Sensors and Intracellular Signaling 258
Hepatic levels of mRNA and protein of genes associated with cellular nutrient 259 sensing, selected for their responsiveness to acute oxygen deprivation (including HIF1α 260 target genes: VEGFA, EPO, EDN1, PFK1, PFKFB1, PDK4, LDHA), were largely 261 unchanged by chronic anemic hypoxemia (Table 3) . Similarly unchanged were 262 intracellular signaling proteins AMPK, CREB and AKT. Chronic anemic hypoxemia 263 reduced hepatic mRNA expression of the glucagon receptor (GCCR) (p<0.05; Table 3) . 264
Fetal Hepatocytes 265
The roles of oxygen and hormone stimulation on expression of genes involved in 266 regulation of HGP were tested in primary fetal sheep hepatocytes. In response to 3% 267 oxygen, mRNA expression of both PCK1 and PGC1A increased 2-3-fold compared to 268 21% oxygen (p<0.001; Figure 6 ). Expression of PCK1 and PGC1A also increased in 269 response to cAMP + dexamethasone treatment (p<0.005; Figure 6 ).
DISCUSSION 271
In this study, we determined that low fetal blood oxygen concentrations as a 272 result of chronic fetal anemia increases circulating glucagon concentrations which were 273 associated with increased hepatic PCK1 mRNA and decreased hepatic glycogen 274 content. These results show that fetal anemic hypoxemia is sufficient to stimulate and 275 sustain increases in factors which are associated with activation of both 276 gluconeogenesis and glycogenolysis. Furthermore, these results demonstrate that fetal 277 hypoglycemia (a hallmark of PI-IUGR) is not necessary for this response, even though it 278 can, by itself, lead to fetal HGP (21). Supporting this conclusion is our finding that 279 exposure to either 3% oxygen or glucogenic activators (cAMP + dexamethasone) 280 increases expression of PCK1 and PGC1A in isolated fetal hepatocytes. This is the first 281 study to test the impact of chronic (>24 hours) fetal anemic hypoxemia independent of 282 placental insufficiency and fetal hypoglycemia on fetal metabolic and endocrine 283 responses, thereby identifying novel mechanisms by which fetal oxygen concentrations 284 can regulate fetal glucose metabolism. 285
To determine the fetal endocrine response to anemic hypoxemia we measured 286 the concentrations of several hormones throughout the study. Fetal glucagon 287 concentrations increased in the anemic group and correlated with both PCK1 and G6PC 288 mRNA. Glucagon has been previously shown to activate fetal HGP, but the 289 concentrations of glucagon required were greater than 1,000 pg/mL, suggesting fetal 290 hepatic resistance to glucagon relative to adults (10, 45). In our study, physiological 291 concentrations of glucagon, 20-80 pg/mL, correlated with higher PCK1 and G6PC 292 mRNA levels. It may be that fetal anemic hypoxemia augments the physiologicalhyperglucagonemia leading to the transcriptional activation of PCK1, while in fetal 294 normoxemia much higher concentrations of glucagon are required to stimulate fetal 295 gluconeogenesis. Lower hepatic glucagon receptor mRNA levels in anemic fetuses is 296 evidence of ongoing hepatic glucagon signaling, consistent with a dose dependent 297 decrease in GCCR mRNA in primary hepatocytes following incubation with glucagon 298
(1). 299
Fetal cortisol concentrations increased in the anemic fetuses, but also started 300 lower than controls. By the end of the study, cortisol concentrations were not different 301 between the two groups. These mixed results make it difficult to speculate about the 302 role of cortisol in regulating hepatic PCK1 in this set of animals, despite the well-303 described role for cortisol in activating gluconeogenesis (12, 13, 38) . Whether this 304 represents another pathway partially responsible for the hepatic phenotype in anemic 305 fetuses is not clear. In order to demonstrate the capacity of hormone signaling, as well 306 as oxygen to increase PCK1 and G6PC mRNA, we performed in vitro studies with 307 isolated fetal hepatocytes. cAMP + dexamethasone treatment increased PCK1 mRNA 308 levels in these cells. Interestingly, although we did not detect increased hepatic PGC1A 309 mRNA in the anemic fetuses, both 3% oxygen and cAMP + dexamethasone treatment 310 in isolated hepatocytes increased PGC1A expression. Thus, oxygen clearly has the 311 capacity to increase hepatocyte PGC1A expression, but in vivo fetal hypoxemia does 312
not. 313
Since physiological increases in glucagon were associated with increased 314 hepatic expression of gluconeogenic genes, we analyzed components of the cAMP-315 dependent glucagon-signaling pathway. PI-IUGR fetuses have activation of PCK1associated with increased glucagon, PGC1α (PGC1A) and phosphorylated CREB (29, 317 48). However, we found no change in PGC1A or phosphorylated CREB in the livers of 318 anemic fetuses on the terminal day of the study. This may be due to three factors. First, 319 levels may have been increased earlier in the study representing an acute fetal 320 response to hypoxemia (2, 41). Second, there may be fundamental differences in the 321 fetal response to chronic hypoxemia and PI-IUGR. Fetuses affected by PI-IUGR 322 experience global nutrient restriction, including reduced oxygen supply and blood 323 concentrations (47, 48). Further, this oxygen deprivation occurs throughout most of the 324 latter half gestation, in contrast to the nine days of anemic hypoxemia tested in the 325 current model. Factors other than fetal hypoxemia, to which the fetus is exposed for 326 longer than nine days, may be responsible for increased PGC1A and phosphorylated 327 CREB in PI-IUGR. Third, and likely related to the duration and global nutrient restriction 328 noted above, PI-IUGR fetuses have a much more robust increase in PCK1 and G6PC 329 mRNA levels compared to the anemic fetuses (29, 30, 47, 48) . The modest increase in 330 PCK1 and G6PC mRNA in the anemic livers compared to models of placental 331 insufficiency is consistent with the similar level of hepatic protein expression of PEPCK. 332
It is notable that while both PI-IUGR and anemic fetuses have increased hepatic PCK1, 333 substantial differences in hepatic signaling are apparent, likely due to different hepatic 334 nutrient (glucose and oxygen) supplies. 335
We did not find any differences in hepatic AMPK phosphorylation or GRP78, two 336 proteins normally activated by acute nutrient deprivation and/or hypoxemia (Table 3 ) 337 (18, 24). Three reasons may account for this lack of activation. First, although AMPK 338 and GRP78 are activated by hypoxemia, the anemic animals did not have a significantdecrease in their PO 2 compared to controls and hepatocytes might not have 340 experienced tissue hypoxia, which may be required to activate AMPK and GRP78 (18, 341 24, 48) . Supporting the conclusion that the liver did not experience hypoxia is the lack of 342 change noted in any hypoxia responsive genes, such as VEGFA, EPO, EDN1, PFK1, 343 PFKBP1, LDHA, PDK4, DDIT3, and HSPA5 (8, 9, 43) . Second, although anemic 344 fetuses had low oxygen content, they were not deprived of glucose or lactate, which 345 also are important for activating AMPK and GRP78 (48). Lastly, most studies 346 demonstrating activation of AMPK and GRP78 focus on acute oxygen deprivation, often 347 in vitro (18, 24) . 348
Fetal oxygen utilization was significantly decreased in the anemic group 349 compared to controls. This is despite higher oxygen extraction in the anemic fetuses. In 350 previous reports (4, 52), fetuses were shown to be able to maintain normal oxygen 351 utilization during graded reductions in oxygen supply produced experimentally by partial 352 occlusion of the maternal terminal aorta causing uterine blood flow restriction. This 353 increased oxygen extraction enabled normal fetal oxygen utilization during graded 354 hypoxemia in this model. In contrast, the anemic fetuses in the present study were 355 unable to maintain oxygen utilization despite increased fetal oxygen extraction. In the 356 uterine blood flow restriction paradigm, the effect of acute hypoxemia on fetal oxygen 357 consumption was tested (4, 52). In the current study we tested the effects over a more 358 prolonged period (nine days). Indeed, in chronic hypoxemia due to placental 359 insufficiency, fetal sheep also tend to have slightly lower oxygen consumption rates than 360
normal (47). 361
We also have shown in the current studies that chronic fetal anemic hypoxemiaincreased fetal glucose concentrations without a change in fetal insulin concentrations. 363
This was not due to an increase in the rate of placental glucose transfer as a possible 364 cause of elevated fetal glucose in anemia. Elevated fetal glucose concentrations in 365 anemic fetuses were likely mediated by high fetal glucagon and cortisol concentrations. 366
Even the slight, though not statistically significant, increase in mean fetal norepinephrine 367 concentrations may have played a role (27, 30, 31) . As the focus of the current study 368 was on the factors which regulate fetal HGP, we did not determine the relative 369 contribution of HGP and decreased fetal glucose utilization for the increase in fetal 370 glucose concentrations. 371
The model of anemia, or reduced oxygen carrying capacity, for hypoxemia was 372 chosen because it did not allow fetuses to compensate by increasing total hemoglobin, 373
and because we could isolate the effects of hypoxemia from hypoglycemia. Kitanaka 374 and colleagues (23) showed that fetuses exposed to 28 days of hypoxemia via high 375 altitude responded by increasing their hemoglobin and hematocrit over time to 376 normalize arterial oxygen contents; these fetuses grew at normal rates, indicative of 377 normal fetal nutrient metabolism. In contrast, our model allowed us to chronically match 378 the mean oxygen content of PI-IUGR fetuses (2.0 mmol/L) (7, 28, 47) . However, 379
comparison of sheep models of human PI-IUGR fetuses exposes limitations of this 380 study, including length and timing of hypoxemia. Studies done to model chronic PI-381 IUGR in sheep result in fetal hypoxemia beginning as early as day 90 in gestation (33) . 382
In the current study, fetal hypoxemia occurred on average for nine days at 0.85 383 gestation. In contrast, the chronically anemic fetal sheep is an appropriate model for 384 human chronic fetal anemia, such as occurs in chronic feto-maternal hemorrhage andsubacute placental abruption; and also may help model aspects of fetal hypoxemia 386 observed in cases of twin-twin transfusion syndrome and diabetic pregnancy and some 387 cases of post-dates pregnancies (3, 42, 46) . Future studies to induce experimental 388 anemia earlier in gestation are planned. The studies also are limited by the random 389 allocation of all female fetuses into the control group. We chose to include all animals in 390 the anemic group as we have never detected sex differences in outcomes reported (29, 391 38, 47, 48, 50) . Furthermore, for the most important outcomes, PCK1 mRNA, G6PC 392 mRNA, and glucagon concentrations, the two highest values in the anemic group were 393 females and the mean concentrations within the anemic group were higher for females 394 than males. 395
PERSPECTIVES AND SIGNIFICANCE 396
In conclusion, we speculate that in pregnancies complicated by fetal hypoxemia, 397 such as intrauterine growth restriction, low oxygen concentrations in conjunction with 398 elevated glucagon play a role in activating factors associated with fetal hepatic 399 gluconeogenesis and glycogenolysis resulting in HGP. These are important findings, as 400 complications of pregnancy that lead to premature activation of fetal HGP predispose to 401 later life development of hepatic insulin resistance, hyperglycemia, and ultimately Type 402 II diabetes mellitus by unknown mechanisms (35, 49, 51) . 403
GRANTS 405
PJR was supported by NIH Grants R01DK088139 and K08 HD060688 (PJR, PI). LDB 406 was supported by NIH Grants K12HD057022 Building Interdisciplinary Careers in 407
Women's Health Scholar Award, and R01HD079404-01A1. SRW was supported by 408 K01DK090199 and R03 DK102972. WWH was supported by NIH Grants T32007186-32 409 (PI and PD), K12HD068372 (PD), and NIH-NCATS UL1TR001082, TL1TR001081, and 410
KL2TR001080 (Co-Director), and a Grand Challenges Exploration Grant from the Bill 411
and Melinda Gates Foundation (OPP1061082). The content is solely the responsibility 412 of the authors and does not necessarily represent the official views of the NIDDK or 413
NICHD. 414 415
DISCLOSURES 416
The authors have nothing to disclose. 417
1.
Abrahamsen N, Lundgren K, Nishimura E. 1.00 ± 0.36 1.54 ± 0.95 Endothelin 1 (EDN1)
1.00 ± 0.17 0.81 ± 0.06 Phosphofructokinase 1 (PFK1)
1.00 ± 0.27 1.59 ± 0.21 6-phospho-2-kinase/fructose 2,6 bisphosphatase 1 1.00 ± 0.27 0.39 ± 0.07* (PFKFB1) Lactate dehydrogenase A (LDHA)
1.00 ± 0.14 1.26 ± 0.42 Pyruvate dehydrogenase kinase 4 (PDK4)
1.00 ± 0.31 0.84 ± 0.41 DNA Damage Inducible Transcript 3 (DDIT3)
1.00 ± 0.11 0.85 ± 0.08 Heat Shock 70kDa Protein 5 (HSPA5)
1.00 ± 0.10 0.73 ± 0.07* Glucagon Receptor (GCGR)
1.00 ± 0.11 0.77 ± 0.06* Hepatic Proteins PEPCK (to Actin) 1.00 ± 0.10 1.12 ± 0.10 Glucose-6-phosphatase (to Actin)
1.00 ± 0.27 0.88 ± 0.30 Total AMPK (to Actin)
1.00 ± 0.30 0.55 ± 0.14 T172 phosphorylated AMPK (to total)
1.00 ± 0.19 0.95 ± 0.13 Total CREB (to Actin)
1.00 ± 0.31 1.23 ± 0.24 S133 phosphorylated CREB (to total)
1.00 ± 0.28 1.17 ± 0.27 Total AKT (to Actin)
1.00 ± 0.09 1.02 ± 0.09 S473/T308 phosphorylated AKT (to total)
1.00 ± 0.10 0.98 ± 0.19 HNF4α (to Actin)
1.00 ± 0.12 1.05 ± 0.20 GRP78 (to Actin)
1.00 ± 0.37 0.70 ± 0.22 Values are expressed as means ± SE. n=7 for control and n=10 for anemic. Statistical significance (p≤0.05) is indicated by an asterisk (*). Figure 6. PCK1 and PGC1A mRNA are increased in fetal hepatocytes incubated in 3% oxygen compared to 21%.
